Biomea Fusion upgraded by Rodman & Renshaw with a new price target
$BMEA
Biotechnology: Pharmaceutical Preparations
Health Care
Rodman & Renshaw upgraded Biomea Fusion from Neutral to Buy and set a new price target of $18.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2025 | $7.00 | Overweight | Piper Sandler |
| 10/9/2024 | $128.00 | Buy | Edward Jones |
| 9/27/2024 | $18.00 | Neutral → Buy | Rodman & Renshaw |
| 9/27/2024 | $54.00 | Hold → Buy | Truist |
| 8/29/2024 | $25.00 | Overweight | CapitalOne |
| 6/11/2024 | Buy → Hold | Truist | |
| 6/7/2024 | $30.00 → $5.00 | Overweight → Equal Weight | Barclays |
| 4/2/2024 | $51.00 → $14.00 | Overweight → Neutral | JP Morgan |